Related Experiment Video
Updated: Aug 2, 2025
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Endothelial Dysfunction in Breast Cancer Survivors on Aromatase Inhibitors: Changes over Time.
Adnan Shaaban1, Ashley Petersen2, Heather Beckwith2
1The Ohio State University.
Aromatase inhibitors (AIs) may cause endothelial dysfunction in breast cancer survivors within six months. Further research is needed to determine if these vascular changes are reversible after AI discontinuation.
Area of Science:
- Oncology
- Cardiology
- Vascular Biology
Background:
- Aromatase inhibitors (AIs) are standard adjuvant therapy for estrogen-receptor positive breast cancer in postmenopausal women.
- The long-term cardiovascular (CV) impact of AIs is not fully understood, necessitating research into their effects on blood vessels in cancer survivors.
Conclusions:
- Aromatase inhibitor therapy may lead to early endothelial dysfunction in postmenopausal breast cancer survivors, a potential predictor of adverse cardiovascular disease.
- Long-term AI use might cause persistent endothelial dysfunction, and reversibility after discontinuation requires further investigation.
More Related Videos
10:36Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015